Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction

Area of Science:

• Cardiology
• Pharmacology
• Medical Imaging

Background:

• Assessing cardiotoxicity of new drug compounds is vital for public health and patient safety.
• Cardiac imaging plays an increasing role in evaluating drug-induced myocardial dysfunction.
• Optimal imaging modality and monitoring frequency for drug-induced cardiac dysfunction remain undefined.

Purpose of the Study:

• To summarize discussions on selecting nonclinical and clinical cardiac function imaging techniques in drug development.
• To guide benefit-risk assessments for potentially cardiotoxic new compounds.
• To highlight key factors in choosing appropriate cardiac imaging modalities.

Main Methods:

• Focus on three common cardiac imaging modalities: echocardiography, magnetic resonance imaging (MRI), and radionuclide (nuclear) imaging.
• Summarize scientific discussions from the Cardiac Safety Research Consortium.
• Review factors influencing modality selection, including sensitivity, specificity, availability, cost, and safety.

Main Results:

• The selection of cardiac imaging techniques is complex due to varying modality characteristics and the unpredictable time course of cardiac injury.
• Echocardiography, MRI, and nuclear imaging are frequently used but require careful consideration for specific applications.
• The paper identifies areas requiring further research in cardiac imaging for drug development.

Conclusions:

• Informed selection of cardiac imaging modalities is essential for accurate benefit-risk assessment of new drugs.
• Standardized guidelines are needed for the optimal use and frequency of cardiac imaging in drug-induced cardiotoxicity monitoring.
• Future research should address current gaps in understanding and application of cardiac imaging techniques.